Concepedia

Elizabeth Fassbender

EF

4

Publications

191

Citations

4

H-Index

2014

Active since

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

Elizabeth Fassbender is an author at Novartis (United States) specializing in drug discovery, glaucoma, and medicine.

Top concepts

Publications per year

2014–2018

4

Publications

4

Reliability of the Mouse Model of Choroidal Neovascularization Induced by Laser Photocoagulation

Stephen Poor, Yubin Qiu, Elizabeth Fassbender et al. · Investigative Ophthalmology & Visual Science · 2014 · 72 citations · Full text

Long-acting protein drugs for the treatment of ocular diseases

Joy G. Ghosh, Andrew Nguyen, Chad E. Bigelow et al. · Nature Communications · 2017 · 54 citations · Full text

The Discovery of <i>N</i>-(1-Methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1<i>H</i>-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration

Christopher M. Adams, Karen Anderson, Gerald D. Artman et al. · Journal of Medicinal Chemistry · 2018 · 36 citations · Full text

, , +17

Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration

Erik L. Meredith, Nello Mainolfi, Stephen Poor et al. · Journal of Medicinal Chemistry · 2015 · 29 citations · Full text

, , +13

Rows per page

1–4 of 4